Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Cancer Discovery|December 21, 2013
Antiangiogenic therapies: going beyond their limitsLidia Moserle, Gabriela Jiménez-Valerio, Oriol Casanovas
Molecular Aspects of Medicine|February 20, 2007
Angiogenesis meets immunology: cytokine gene therapy of cancerSonia Minuzzo, Lidia Moserle, Stefano Indraccolo, et al.
Cancer Letters|June 16, 2009
Side population and cancer stem cells: therapeutic implicationsLidia Moserle, Margherita Ghisi, Alberto Amadori, et al.
Scientific Reports|August 21, 2020
Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predispositionSimona Agata, Silvia Tognazzo, Elisa Alducci, et al.
Human Gene Therapy|August 4, 2005
Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibitionStefano Indraccolo, Veronica Tisato, Valeria Tosello, et al.
The Journal of Clinical Investigation|June 3, 2004
The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignanciesIrma Airoldi, Emma Di Carlo, Barbara Banelli, et al.
Carcinogenesis|October 31, 2014
DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID miceSonia Minuzzo, Valentina Agnusdei, Irene Pusceddu, et al.
Carcinogenesis|February 25, 2009
Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancerLuca Persano, Lidia Moserle, Giovanni Esposito, et al.
Cancer Research|July 18, 2008
The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effectsLidia Moserle, Stefano Indraccolo, Margherita Ghisi, et al.
Cancer Research|February 12, 2009
Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancyStefano Indraccolo, Sonia Minuzzo, Massimo Masiero, et al.
Pageof 3